NeuBase Therapeutics Inc. (NASDAQ:NBSE) shares traded -21.43% lower at $1.87 on Wall Street last session.
In accordance with the data, 1 analysts cover NeuBase Therapeutics Inc. (NASDAQ:NBSE). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $200.00 and a low of $200.00, we find $200.00. Given the previous closing price of $2.38, this indicates a potential upside of 8303.36 percent. NBSE stock price is now 41.44% away from the 50-day moving average and -44.79% away from the 200-day moving average. The market capitalization of the company currently stands at $4.58M.
It has been rated a hold by 1 analysts and a buy by 0. Brokers who have rated the stock have averaged $200.00 as their price target over the next twelve months.
With the price target enhanced from $15 to $18, H.C. Wainwright maintained Buy rating for NeuBase Therapeutics Inc. (NASDAQ: NBSE).
In other news, Symetryx Corp, 10% Owner bought 61,076 shares of the company’s stock on Sep 01. The stock was bought for $59,732 at an average price of $0.98. Upon completion of the transaction, the 10% Owner now directly owns 680,081 shares in the company, valued at $1.27 million. A total of 2.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NBSE stock. A new stake in NeuBase Therapeutics Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $311,000. JPMORGAN CHASE & CO invested $1,000 in shares of NBSE during the first quarter. In the first quarter, ROYAL BANK OF CANADA acquired a new stake in NeuBase Therapeutics Inc. valued at approximately $1,000. In total, there are 39 active investors with 37.20% ownership of the company’s stock.
NeuBase Therapeutics Inc. (NASDAQ: NBSE) opened at $1.6800 on Thursday. During the past 12 months, NeuBase Therapeutics Inc. has had a low of $0.61 and a high of $12.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.50, and a quick ratio of 2.50. The fifty day moving average price for NBSE is $1.2890 and a two-hundred day moving average price translates $3.3219 for the stock.
The latest earnings results from NeuBase Therapeutics Inc. (NASDAQ: NBSE) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$2.04, missing analysts’ expectations of -$2 by -0.04. This compares to -$5.26 EPS in the same period last year. The company reported revenue of $3.69 million for the quarter, compared to $8.36 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -55.89 percent.
NeuBase Therapeutics Inc.(NBSE) Company Profile
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington’s disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
